<p>The CS-MATCH-0007 protocol is part of a collaboration between the Center for Cancer Genomics (CCG) and the Division of Cancer Treatment and Diagnosis (DCTD) to perform whole-exome sequencing and RNA sequencing using pre-and post-treatment tumor biopsy specimens from patients enrolled on a treatment arm of the <a href="https://classic.clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&#x26;rank=1">NCI-MATCH Clinical Trial (EAY131)</a>. The goal of this study is to identify the molecular basis for response and resistance to targeted therapies that are matched to specific genomic alterations found in their cancers. Arm S1 is one of the treatment sub-protocols within the <a href="https://classic.clinicaltrials.gov/ct2/show/NCT02465060?term=NCT02465060&#x26;rank=1">NCI-MATCH Clinical Trial (EAY131)</a> where patients with NF1 mutations are treated with Trametinib. This subprotocol is one of the treatment arms included in the CS-MATCH-0007 protocol and will provide specimens for the program including DNA from tumor tissue and whole blood.</p>

Genomic Characterization CS-MATCH-0007 Arm S1

Neoplasms study on CRDC (41 participants)